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Abstract
We present a clinical case of a patient with SARS-CoV-2 infection and respiratory symptoms, complicated with a pro-thrombotic
state involving multiple vascular territories and concomitant interleukin-6 increase. This case underlines the possibility to
develop a COVID-19-related coagulopathy.
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Introduction
Systemic and neurological complications of SARS-CoV-2 in-
fection are increasingly recognized. Several studies described
the typical clinical presentation with fever, cough, and fatigue
(Lovato and De Filippis 2020). Most recent publications
(Klok et al. 2020) showed how COVID-19 might involve
not only the respiratory system but also cause a pro-
thrombotic state leading to peripheral veins thrombosis and
pulmonary embolism. Here, we report a case of a patient with
SARS-CoV-2 infection that developed severe coagulopathy
affecting both pulmonary and cerebral vessels.
Clinical case
A 62-year-old patient presented to our emergency room with
fever and dyspnea.
He was affected by diabetes mellitus, ankylosing spondy-
litis previously treated with Adalimumab and currently on
Secukinumab, and complicated with pulmonary fibrosis.
He was firstly admitted to infectious diseases ward. A na-
sopharyngeal swap for SARS-CoV-2 resulted positive. Blood
exams showed normal white blood cells with low lymphocyte
levels and platelet counts, increased levels of D-dimer and
lactate dehydrogenase (LDH), and slightly increased C-
reactive protein (CRP). Interleukin-6 (IL-6) was also elevated
(Table 1).
Therapies with oxygen, hydroxychloroquine, and prophy-
lactic low molecular weight heparin (LMWH) were started. In
the following days, the patient respiratory symptoms wors-
ened with increasing need for oxygen therapy. Three days
after admission, a marked increase in D-dimer was noted. D-
dimer remained elevated in the following days (Fig. 1). Seven
days after the admission, he suddenly developed respirato-
ry insufficiency not responding to high flow oxygen ad-
ministration, requiring ICU admission and mechanical
ventilation. Blood exams were repeated; D-dimer was still
markedly elevated; in comparison with the exams at admis-
sion, increased IL-6 (Fig. 1), severe thrombocytopenia, and
only mildly increased prothrombin time and partial throm-
boplastin time were noted. Of interest, LDH, CRP, and
procalcitonin were stable (Table 1). Two days later, at the
weaning of anesthesia, the patient presented with left hemi-
plegia, left hemianopsia, and forced right deviation of
gaze. A brain CT showed a wide infarction involving deep
and superficial territories of the right middle cerebral artery
and a smaller left subcortical infarction. Furthermore, a
chest CT-angiography was performed, showing bilateral
pulmonary embolism and confirming a severe interstitial
involvement of the lungs. Ecocolordoppler of supra-aortic
vessels was unremarkable, and cardiac monitoring did not
show any arrhythmias. A therapy with anticoagulant dose
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of LMWH was started. Nevertheless, the patient continued
to deteriorate and died 2 days later for respiratory failure.
Discussion
Arterial and venous thrombotic events are recognized compli-
cations of SARS-CoV-2 infection (Klok et al. 2020; Beyrouti
et al. 2020). The mechanism leading to SARS-CoV-2-related
coagulopathy is extensively reviewed elsewhere (Iba et al.
2020). The immune system appears to play a critical role in
the pathogenesis: increased levels of pro-inflammatory cyto-
kines (i.e., IL-6), damage-associated molecular patterns re-
lease, and complement activation may trigger platelets aggre-
gation and coagulation cascade (Iba et al. 2020). Lupus anti-
coagulant and anti-phospholipid antibodies have also been
described in COVID-19 patients with thrombotic events
(Helms et al. 2020; Zhang et al. 2020), but a causal relation
has not been proven. Finally, SARS-CoV-2 might directly
target endothelial vascular cells expressing angiotensin
converting enzyme 2 receptors, necessary for viral adhesion,
leading to endothelial dysfunction and apoptosis with subse-
quent vasoconstriction, inflammation, and procoagulant state
(Varga et al. 2020). Increasing IL-6 plasma concentration dur-
ing hospitalization has been associated with poor outcome
(Zhou et al. 2020); we report a striking increase of IL-6 con-
comitant with respiratory failure and pulmonary embolisms.
Such finding might entail a possible pathogenic role of the
cytokine storm in COVID-19-related coagulopathy, although
a causative role cannot be proven andmore studies are needed.
Of note, severe respiratory failure was heralded by a marked
D-dimer increase 5 days earlier (Fig. 1). Finally, our patient
developed sudden respiratory failure with subsequent need for
intubation and sedation preventing an early recognition of
Fig. 1 D-dimer and interleukin-6
(IL-6) variation in time. The line
shows an important D-dimer in-
crease 5 days before severe respi-
ratory failure. The two dots show
IL-6 level at admission and at the
time of severe respiratory failure
Table 1 Blood examination at
admission (day 0) and at onset of
pulmonary embolism (day 7).
Values below or above normal
limits are marked with *
Day 0 Day 7 Normal values
WBC 6.22 × 103/mm2 11.12 × 103/mm2 * 4.0–10.9 × 103/mm2
Neutrophils 5.43 × 103/mm2 10.46 × 103/mm2 * 1.8–7.7 × 103/mm2
Lymphocytes 0.53 × 103/mm2 * 0.40 × 103/mm2 * 1.0–4.5 × 103/mm2
Hb 14.3 g/dl 12.9 g/dl* 13.5–17.5 g/dl
PTL 117 × 103/mm2 * 68 × 103/mm2 * 150–450 × 103/mm2
INR 0.90 1.29 * 0.84–1.25
D-dimer 740 ng/ml * 31,910 ng/ml * 0–500 ng/ml
Fibrinogen 491 mg/dl * 158 mg/dl * 200–400 mg/dl
LDH 1018 U/l * 1040 U/l * 230–460 U/l
Troponin < 12 ng/l 504 ng/l* < 34 ng/l
CRP 5.2 mg/dl* 4.1 mg/dl* 0–0.7 mg/dl
PCT 0.1 ng/ml 0.1 ng/ml < 0.5 ng/ml
IL-6 72.10 pg/ml * > 2300 pg/ml* 0–10 pg/ml
WBC white blood cell, Hb hemoglobin, PTL platelets, INR international normalized ratio, LDH lactate dehydro-
genase, CRP C-reactive protein, PCT procalcitonin, IL-6 interleukin-6
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stroke that was diagnosed only 2 days later after weaning of
anesthesia. This case underlines the importance of constant
neurological monitoring in COVID-19 patients during ICU
staying, especially in those with suspected thrombotic events,
to detect possible neurological complications. Indeed, stroke
is an emerging complication of SARS-CoV-2 infection, and
revascularization therapies are available, if the diagnosis is
promptly done.
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